Equities

Hi-Great Group Holding Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HIGR:PKC

Hi-Great Group Holding Co

Actions
  • Price (USD)0.0801
  • Today's Change0.00 / 0.00%
  • Shares traded150.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 14:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hi-Great Group Holding Company is a development stage company. The Company focuses on the distribution of plant-based finished consumer products and integrating the use of specialty herbs into its worldwide health supplement business to include expansion into the cosmetics sector using multiple herbal oils and compounds. It plans to grow organically through Internet sales of its worldwide exclusive license agreement with SellaCare, Inc. in the areas of longevity health supplements and plans to integrate new product lines containing cannabidiol (CBD) oils for additional health benefits and also expand into the cosmetic sector.

  • Revenue in USD (TTM)48.03k
  • Net income in USD-64.27k
  • Incorporated2010
  • Employees--
  • Location
    Hi-Great Group Holding Co621 S. Virgil Ave #470LOS ANGELES 90005United StatesUSA
  • Phone+1 (213) 219-7746
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Curative Biotechnology Inc0.00-6.02m7.75m4.00---------0.0105-0.01050.00-0.00180.00----0.00-339.98-----------------5.51---------302.92------
Aclarion Inc67.48k-7.39m7.79m6.00--0.1272--115.48-1,687.50-1,687.500.194821.460.0082--2.7611,246.67-89.50---97.72---7.85---10,868.49-----25,428.220.00---39.36---43.60------
Pharmacyte Biotech Inc0.00-8.98m7.92m2.00--0.1491-----1.32-1.320.005.380.00----0.00-12.747.21-13.517.54------------0.00------235.53------
StimCell Enegetics Inc0.00-935.22k7.94m0.00---------0.0461-0.04610.00-0.07380.00-------2,062.23-844.03-----------18,037.46---17.22---------297.42------
Hi-Great Group Holding Co48.03k-64.27k8.21m--------170.94-0.0006-0.00060.0005-0.0020.72290.5559-----96.73-21.81---256.3538.7745.63-133.81-21.020.0288-------36.79--60.07------
Kiora Pharmaceuticals Inc0.00-8.54m8.28m12.00--0.3447-----2.05-2.050.006.530.00----0.00-24.99-48.77-27.44-56.18-------276.73----0.00----42.93127.56------
Curanex Pharmaceuticals Inc0.00-1.30m8.52m----0.5961-----0.0497-0.04970.000.5043---------------------------142.760.00-------1,782.87------
Edesa Biotech Inc0.00-7.19m8.75m17.00--2.35-----1.35-1.350.001.740.00----0.00-82.86-103.16-99.57-123.95-----------138.680.00-------16.46------
Pulmatrix Inc3.00k-6.22m8.95m2.00--1.89--2,982.70-1.70-1.700.00081.300.0004----1,500.00-75.43-42.08-79.47-49.93-----207,333.30-210.36----0.00--6.96-0.264432.31--46.99--
BioVie Inc0.00-17.48m8.98m13.00--0.4658-----5.13-5.130.002.550.00----0.00-72.35-260.69-79.73-454.45------------0.00------45.73------
Data as of Feb 06 2026. Currency figures normalised to Hi-Great Group Holding Co's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.